📰 Randomized Phase News
Page 5 - Randomized Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Randomized Phase. Real-time updates on events, politics, business and more.
July 6, 2023
Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination...
May 27, 2023
VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like ...
May 26, 2023
Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use...
May 26, 2023
FN Media Group Presents USA News Group News Commentary VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American
May 26, 2023
VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like ...
May 26, 2023
/PRNewswire/ -- USA News Group - The worlds biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...
May 25, 2023
Treatment with Ocrevus reduced B-cells receptors' diversity, but not that of T-cells' receptors, in relapsing MS patients.
May 18, 2023
MIEBO is the First and Only Prescription Eye Drop Approved for Dry Eye Disease that Directly Targets Tear Evaporation, Based on Consistent Results from Two Consecutive Pivotal Phase 3 Trials Bausch
May 17, 2023
– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and... | May 17, 2023
May 10, 2023
A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.